NAAS - CI INVZ and OTLY are among pre market gainers
2023-12-11 08:32:44 ET
- Poseida Therapeutics ( PSTX ) +31% Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting.
- Jet. ( JTAI ) +24% .
- Innoviz Technologies ( INVZ ) +23% .
- Macy's ( M ) +16% stocks rally after Macy's attracts a buyout offer.
- Marker Therapeutics ( MRKR ) +14% Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse.
- Cigna Group ( CI ) +14% .
- Tscan Therapeutics ( TCRX ) +12% .
- Valens Semiconductor ( VLN ) +10% Appoints Guy Nathanzon as Chief Financial Officer.
- Morphosys ( MOR ) +9% Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study.
- Alzamend Neuro ( ALZN ) +9% Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next?Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients.
- Oatly Group ( OTLY ) +8% .
- Redhill Biopharma ( RDHL ) +8% .
- Rubicon Technologies ( RBT ) +7% .
- NeuroOne Medical Technologies ( NMTC ) +6% Receives FDA 510 Clearance to Market its OneR Ablation System.
- View ( VIEW ) +6% .
- Professional Diversity Network ( IPDN ) +6% .
- Naas Technology ( NAAS ) +6% .
For further details see:
CI, INVZ and OTLY are among pre market gainers